A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–99
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of AS or PsA.
Planned prescription or prescribed no more than 1 month before to enrolment therapy with adalimumab. Treatment has to be prescribed according to the local product label and prescription guidelines.
At the moment of start of treatment with adalimumab moderate/severe AS or PsA (BASDAI \> 4 for AS; DAS28 \>3,2 for PsA).
Negative result of tuberculosis (TB) screening test and TB specialist permission to start biologic therapy.
Authorization (Consent) for Use/Disclosure of Data signed by the participant.
You may not be if
Has contraindications for the treatment with adalimumab (please see the latest version of the locally approved label).
Participants who are unable to walk and perform basic self-care activities either due to SpA or a comorbid condition.
Any biologic drugs taken over before 3 months of enrolment to the study.
Previous participation in this program.
Clareo Health | A Study to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
